论文部分内容阅读
在欧洲和美国,β-肾上腺素能阻滞剂有越来越多地替代利尿剂作为第一线高血压的治疗。本文显示β-阻滞剂如何按照其药理学特性分为各亚类,从而在高血压中适当地选择作为初始应用,或在第二阶梯治疗中与利尿剂和其他药物联合应用;同时提出在降低血压中钙拮抗剂和血管紧张素转换酶抑制剂的应用可能性。高血压的β-阻滞药物治疗远在15年前,β-阻滞剂的抗高血压效用已被确立。许多研究者证实在降低血压中长期维持应用的有效性和安全性,而且患者的顺从性水平也较高。由于新的药物改善了药物动力学和药效学特性,而能够在早期发
In Europe and the United States, β-adrenergic blockers increasingly replace diuretics as first-line treatment of hypertension. This article shows how beta-blockers are divided into subgroups according to their pharmacological properties and thus are appropriately selected for use as initial applications in high blood pressure or in combination with diuretics and other medications in second-stage treatment; Potential for reducing the use of calcium antagonists and angiotensin-converting enzyme inhibitors in blood pressure. Antihypertensive efficacy of beta-blockers has been established 15 years ago as beta-blocker therapy for hypertension. Many investigators have demonstrated the effectiveness and safety of long-term maintenance in reducing blood pressure, and their patient compliance is high. Because of the new drugs to improve pharmacokinetics and pharmacodynamics, and can be made in the early stage